TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing
- 1Central South University
Abstract
Identifying differentially expressed genes is fundamental to elucidating the molecular mechanisms underlying complex diseases. However, in complex disorders such as Alzheimer's disease (AD), the genes exhibiting dysregulated expression may vary among patient subsets, reflecting the heterogeneity of the underlying pathological processes. Consequently, pathogenic genes are profoundly dysregulated in only a subset of patients. Conventional differential expression tools, such as DESeq2 and edgeR, are primarily designed to detect population-level expression shifts and may have limited power to identify subgroup-specific dysregulation. To overcome this limitation, we developed TailEnrich, a novel computational method that discovers dysregulated genes within patient subsets. TailEnrich independently tests the extreme left (downregulated) or right (upregulated) tails of a gene's expression distribution for disease sample enrichment. We quantify this enrichment using a new metric, i.e. the PE (Percentage of Enriched disease samples) score. On simulated datasets, TailEnrich demonstrates markedly improved accuracy over DESeq2 and edgeR in identifying dysregulated genes specific to patient subsets. Applied to AD gene expression data, TailEnrich uncovers a distinct, biologically relevant set of genes within key pathological pathways that are missed by mean shift-based approaches. TailEnrich provides a novel method for identifying dysregulated genes, and readily extends to other omics data including genomic variants and proteomics to uncover pathogenic genes in complex diseases.
Related
- Engineering endosperm storage compartments enables simultaneous enrichment of multiple vitamins in rice
- An alignment-last approach enables rapid transcriptomic biomarker discovery in large cohorts
- False discovery rate control enables trustworthy deep-learning-based de novo peptide sequencing
- Tumor-versus-non-tumor T cell enrichment supported by single-cell and spatial phenotyping enables antigen-agnostic prioritization of candidate tumor-reactive TCRs
- Agentic Discovery Transfer Enables Cross-Cancer Discovery at Scale
BibTeX
@misc{li2026tailenrich,
title = {{TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing}},
author = {H. Li and Y. Liu and C. Lin and S. Wang and H. Pan and S. Wang},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.04.764457},
url = {https://www.biorxiv.org/content/10.64898/2026.11.04.764457v1},
note = {CC BY-NC-ND},
}
RIS
TY - UNPB
TI - TailEnrich enables discovery of dysregulated genes through disease sample enrichment testing
AU - H. Li
AU - Y. Liu
AU - C. Lin
AU - S. Wang
AU - H. Pan
AU - S. Wang
PY - 2026
DA - 2026/11/04
PB - bioRxiv
DO - 10.64898/2026.11.04.764457
UR - https://www.biorxiv.org/content/10.64898/2026.11.04.764457v1
AB - Identifying differentially expressed genes is fundamental to elucidating the molecular mechanisms underlying complex diseases. However, in complex disorders such as Alzheimer's disease (AD), the genes exhibiting dysregulated expression may vary among patient subsets, reflecting the heterogeneity of the underlying pathological processes. Consequently, pathogenic genes are profoundly dysregulated in only a subset of patients. Conventional differential expression tools, such as DESeq2 and edgeR, are primarily designed to detect population-level expression shifts and may have limited power to identify subgroup-specific dysregulation. To overcome this limitation, we developed TailEnrich, a novel computational method that discovers dysregulated genes within patient subsets. TailEnrich independently tests the extreme left (downregulated) or right (upregulated) tails of a gene's expression distribution for disease sample enrichment. We quantify this enrichment using a new metric, i.e. the PE (Percentage of Enriched disease samples) score. On simulated datasets, TailEnrich demonstrates markedly improved accuracy over DESeq2 and edgeR in identifying dysregulated genes specific to patient subsets. Applied to AD gene expression data, TailEnrich uncovers a distinct, biologically relevant set of genes within key pathological pathways that are missed by mean shift-based approaches. TailEnrich provides a novel method for identifying dysregulated genes, and readily extends to other omics data including genomic variants and proteomics to uncover pathogenic genes in complex diseases.
ER -